Literature DB >> 2203581

Disease-induced variations in plasma protein levels. Implications for drug dosage regimens (Part II).

R Zini1, P Riant, J Barré, J P Tillement.   

Abstract

Part I of this article, which appeared in the previous issue of the Journal, discussed the implications of variations in plasma protein levels in a number of diseases: hepatic and renal disease, acute myocardial infarction, burns, cancer, diabetes mellitus, hyperlipidaemia and inflammatory diseases. In Part II the authors continue their review with a further range of disease states, and consider their import for drug dosages.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2203581     DOI: 10.2165/00003088-199019030-00005

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  235 in total

1.  The protein binding of some drugs in plasma from patients with alcoholic liver disease.

Authors:  M Affrime; M M Reidenberg
Journal:  Eur J Clin Pharmacol       Date:  1975-04-04       Impact factor: 2.953

Review 2.  Diseases and drug protein binding.

Authors:  J P Tillement; F Lhoste; J F Giudicelli
Journal:  Clin Pharmacokinet       Date:  1978 Mar-Apr       Impact factor: 6.447

Review 3.  Pathophysiologic factors affecting the pharmacokinetics of nonsteroidal antiinflammatory drugs.

Authors:  R K Verbeeck
Journal:  J Rheumatol Suppl       Date:  1988-10

4.  The influence of uremia on pharmacokinetics and protein binding of prednisolone.

Authors:  H Bergrem
Journal:  Acta Med Scand       Date:  1983

5.  Altered plasma protein-binding of prednisolone in patients with the nephrotic syndrome.

Authors:  F J Frey; B M Frey
Journal:  Am J Kidney Dis       Date:  1984-03       Impact factor: 8.860

6.  Tianeptine binding to human plasma proteins and plasma from patients with hepatic cirrhosis or renal failure.

Authors:  R Zini; D Morin; C Salvadori; J P Tillement
Journal:  Br J Clin Pharmacol       Date:  1990-01       Impact factor: 4.335

Review 7.  Neonatal bilirubin toxicity. A review of kernicterus and the implications of drug-induced bilirubin displacement.

Authors:  P C Walker
Journal:  Clin Pharmacokinet       Date:  1987-07       Impact factor: 6.447

8.  Pentobarbital elimination in patients with poor renal function.

Authors:  M M Reidenberg; D T Lowenthal; W Briggs; M Gasparo
Journal:  Clin Pharmacol Ther       Date:  1976-07       Impact factor: 6.875

9.  Plasma protein binding of frusemide in liver disease: effect of hypoalbuminaemia and hyperbilirubinaemia.

Authors:  A Viani; M Carrai; G M Pacifici
Journal:  Br J Clin Pharmacol       Date:  1989-08       Impact factor: 4.335

10.  Kinetics of salicylate elimination by anephric patients.

Authors:  D T Lowenthal; W A Briggs; G Levy
Journal:  J Clin Invest       Date:  1974-11       Impact factor: 14.808

View more
  8 in total

Review 1.  Effect of diabetes mellitus on pharmacokinetic and pharmacodynamic properties of drugs.

Authors:  Miroslav Dostalek; Fatemeh Akhlaghi; Martina Puzanovova
Journal:  Clin Pharmacokinet       Date:  2012-08-01       Impact factor: 6.447

2.  Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study.

Authors:  Joachim Stangier; Karin Rathgen; Hildegard Stähle; Dago Mazur
Journal:  Clin Pharmacokinet       Date:  2010-04       Impact factor: 6.447

Review 3.  Drug dosage in patients during continuous renal replacement therapy. Pharmacokinetic and therapeutic considerations.

Authors:  P Reetze-Bonorden; J Böhler; E Keller
Journal:  Clin Pharmacokinet       Date:  1993-05       Impact factor: 6.447

Review 4.  Considerations in dosage selection for third generation cephalosporins.

Authors:  J H Yuk-Choi; C H Nightingale; T W Williams
Journal:  Clin Pharmacokinet       Date:  1992-02       Impact factor: 6.447

5.  Effect of severe renal failure and haemodialysis on the pharmacokinetics of levosimendan and its metabolites.

Authors:  Jaakko Puttonen; Sampo Kantele; Matti Kivikko; Sari Häkkinen; Veli-Pekka Harjola; Petri Koskinen; Pertti J Pentikäinen
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 6.  Drug administration in patients with renal insufficiency. Minimising renal and extrarenal toxicity.

Authors:  G R Matzke; R F Frye
Journal:  Drug Saf       Date:  1997-03       Impact factor: 5.606

7.  Effect of impaired renal function and haemodialysis on the pharmacokinetics of aprepitant.

Authors:  Arthur J Bergman; Thomas Marbury; Trisha Fosbinder; Suzanne Swan; Lisa Hickey; Thomas E Bradstreet; John Busillo; Kevin J Petty; Kala-Jyoti Viswanathan Aiyer; Marvin Constanzer; Su-Er W Huskey; Anup Majumdar
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 5.577

8.  Changes in the pharmacokinetic of sildenafil citrate in rats with Streptozotocin-induced diabetic nephropathy.

Authors:  Alok S Tripathi; Papiya M Mazumder; Anil V Chandewar
Journal:  J Diabetes Metab Disord       Date:  2014-01-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.